Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allergy Therapeutics ( (GB:AGY) ) just unveiled an announcement.
Allergy Therapeutics plc reported that all resolutions at its 2026 Annual General Meeting were passed on a show of hands, reflecting strong shareholder backing for the company’s governance and strategic direction. Shareholders approved the 2025 accounts, the directors’ remuneration report, the election of new board members Helge Weiner-Trapness and Lawrence Allen Wang, and the re-election of existing directors, alongside the reappointment of BDO LLP as auditors. They also granted the board authority to allot shares and equity securities and approved amendments to the Articles of Association, providing the company with continued financial and operational flexibility to support its growth plans within the allergy immunotherapy market.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, which poses significant risks. Despite strong technical indicators suggesting bullish momentum, the overbought condition may lead to a correction. The negative P/E ratio and lack of dividend yield further detract from the stock’s attractiveness.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics plc is a fully commercial biotechnology company specialising in allergy immunotherapies. Listed on AIM, the Group focuses on developing and marketing treatments for allergy sufferers, positioning itself within the niche of allergy-focused biopharmaceuticals.
Average Trading Volume: 371,042
Technical Sentiment Signal: Buy
Current Market Cap: £730.8M
See more data about AGY stock on TipRanks’ Stock Analysis page.